Hard chambers vs soft (mild) chambers

What is the difference between hard and soft hyperbaric chambers?

Hard chambers are rigid steel or acrylic vessels that reach 2.0 to 2.4 ATA with close to 100% oxygen, while soft ('mild hyperbaric') chambers are inflatable fabric enclosures rated near 1.3 ATA and typically run on concentrator oxygen. Because dose scales with pressure and oxygen fraction together, the difference compounds into a substantially smaller exposure.

Hyperbaric chambers fall into two broad classes, and the difference is not a matter of degree in the way the naming suggests.

Hard chambers are rigid pressure vessels — steel or thick acrylic — rated for clinical pressures. They come as monoplace (one patient, lying down) or multiplace (room-sized, several patients seated with an attendant). They routinely operate at 2.0 to 2.4 ATA and deliver close to 100% oxygen, either by flooding the chamber or via mask or hood.

Soft chambers, often marketed as 'mild hyperbaric', are inflatable fabric enclosures. They are typically rated to around 1.3 ATA and are commonly used with an oxygen concentrator rather than a 100% oxygen supply.

The gap between those two is not small. Because the dissolved oxygen in plasma scales with the partial pressure of oxygen you are breathing, both halves of the difference compound: lower pressure and a lower oxygen fraction multiply out to a substantially smaller dose.

Has any published hair-transplant HBOT protocol used a soft chamber?

No published hair-transplant HBOT study has used a soft chamber. The Fan trial used 100% oxygen at 2.0 ATA for 60 minutes daily over seven days, Giardiello's used a monoplace chamber at 2.4 ATA for 90 minutes over six days, and Lee's used 2.0 ATA with 100% oxygen for 90 minutes — all hard-chamber protocols.

Every published clinical protocol in this field used hard-chamber pressures. Fan and colleagues used 100% oxygen at 2.0 ATA for 60 minutes daily for seven days. Giardiello and colleagues used a monoplace chamber at 2.4 ATA for 90 minutes daily for six days. Lee and colleagues, studying follicle characteristics in healthy volunteers, used 2.0 ATA and 100% oxygen for 90 minutes.

None used a soft chamber. So the question of whether a soft chamber delivers the same benefit after a hair transplant does not have a weak answer in the literature — it has no answer at all, because it has never been studied in this setting.

That is a straightforward and important point to make to a clinic. If HBOT is being offered on the strength of the published research, the chamber has to reproduce the exposure the published research used. If it does not, the research is not evidence for what is being sold.

Is a soft chamber useless

Not necessarily — mild hyperbaric exposure has its own research literature, including work showing it can activate epidermal basal cell proliferation in aged mice. But a soft chamber is not a substitute for the studied hard-chamber protocol: the already-thin hair-transplant evidence base at 2.0-2.4 ATA does not transfer down to 1.3 ATA.

Not necessarily, and it is worth being fair here. There is a research literature on mild hyperbaric exposure, and there are physiological effects described at lower pressures — for instance, work on mild hyperbaric oxygen activating proliferation of epidermal basal cells in aged mice, cited in the correspondence around the Fan trial.

What cannot be said is that a soft chamber is a substitute for the studied protocol. Those are different exposures with different evidence bases, and the evidence base for the hair-transplant indication — which is already thin at 2.0-2.4 ATA — does not transfer down to 1.3 ATA.

How do the safety risks differ between hard and soft hyperbaric chambers?

Soft chambers carry lower barotrauma and oxygen-toxicity risk because both pressure and oxygen dose are lower, but they are frequently run without the trained hyperbaric staff, contraindication screening, or emergency protocols that hard clinical chambers require — and pneumothorax and fire risk remain real concerns in any oxygen-enriched enclosure regardless of pressure.

The risk profile differs in both directions, and it is not simply that soft chambers are safer.

• Lower pressure means less barotrauma risk. Middle ear barotrauma is dose-dependent, so a smaller pressure change is easier on the ears.
• Lower oxygen dose means less oxygen toxicity risk. The seizure risk associated with CNS oxygen toxicity is a function of oxygen partial pressure and exposure duration.
• But supervision is often lower too. Hard clinical chambers are run by trained hyperbaric staff with contraindication screening and emergency protocols. Soft chambers in cosmetic settings frequently are not, and the contraindications that matter — pneumothorax above all — do not disappear because the pressure is lower.
• And fire safety is a real consideration in any oxygen-enriched enclosure, which is one of the reasons clinical chambers have the engineering they do.

What two questions should you ask a clinic about their HBOT chamber?

Ask what pressure the chamber reaches in ATA, and whether you'll breathe 100% oxygen or concentrator output. Answers of 2.0-2.4 ATA and 100% oxygen match the published studies' exposure; answers around 1.3 ATA with concentrated oxygen describe a different treatment that should not be priced or marketed as equivalent.

Two questions settle it: what pressure does the chamber reach, in ATA, and am I breathing 100% oxygen or concentrator output.

If the answers are 2.0-2.4 ATA and 100% oxygen, you are being offered the exposure the published studies used — with all the caveats about how limited those studies are. If the answers are around 1.3 ATA and concentrated oxygen, you are being offered something else, and it should not be priced or described as if it were the same treatment.

This distinction is worth insisting on, because it is one of the clearest places where an adjunct can be marketed on the back of research that does not apply to it.

Sources

1. Fan Z, Gan Y, Qu Q, Wang J, Lunan Y, Liu B, Chen R, Hu Z, Miao Y. The effect of hyperbaric oxygen therapy combined with hair transplantation surgery for the treatment of alopecia. Journal of Cosmetic Dermatology, 2021;20(3):917-921. pubmed.ncbi.nlm.nih.gov/32770782
2. Giardiello F, De Medeiros Quirino L, Brigante R, Chumak M. Hyperbaric Oxygen Therapy for Enhanced Postoperative Recovery in Hair Transplantation. Cureus, 2025;17(12):e99635. doi.org/10.7759/cureus.99635
3. Lee HY, Lee JY, Kim SC, Lee Y. Preliminary Effects of Hyperbaric Oxygen Therapy on Hair Follicle Characteristics in Healthy Subjects. Bioengineering, 2026;13(2):240. doi.org/10.3390/bioengineering13020240
4. Heyboer M, Sharma D, Santiago W, McCulloch N. Hyperbaric Oxygen Therapy: Side Effects Defined and Quantified. Advances in Wound Care, 2017;6(6):210-224. pubmed.ncbi.nlm.nih.gov/28616361
5. Dong X, Jin X. The effect of hyperbaric oxygen therapy combined with hair transplantation surgery for the treatment of alopecia [letter to the editor]. Journal of Cosmetic Dermatology, 2021. doi.org/10.1111/jocd.14131

This article summarises published research and standard clinical practice. It is general educational information, not medical advice, and it does not replace the instructions your own surgical team gives you. Where their guidance differs from anything here, follow theirs.